PARP inhibitor treatment in ovarian and breast cancer

Curr Probl Cancer. 2011 Jan-Feb;35(1):7-50. doi: 10.1016/j.currproblcancer.2010.12.002.
No abstract available

Publication types

  • Evaluation Study
  • Review

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics
  • Carcinoma / drug therapy*
  • Carcinoma / genetics
  • DNA Repair / genetics
  • Enzyme Inhibitors / administration & dosage
  • Enzyme Inhibitors / therapeutic use*
  • Female
  • Humans
  • Models, Biological
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / genetics
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Poly(ADP-ribose) Polymerases / genetics
  • Poly(ADP-ribose) Polymerases / metabolism

Substances

  • Enzyme Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases